Unique ID issued by UMIN | UMIN000013954 |
---|---|
Receipt number | R000013476 |
Scientific Title | A multi-facility collaborative controlled trial of the effects of teriparatide on bone union in fragility fractures of patients with osteoporosis (exploratory research) |
Date of disclosure of the study information | 2014/05/14 |
Last modified on | 2017/11/15 09:19:01 |
A multi-facility collaborative controlled trial of the effects of teriparatide on bone union in fragility fractures of patients with osteoporosis (exploratory research)
Teriparatide multi-facility collaborative controlled trial
A multi-facility collaborative controlled trial of the effects of teriparatide on bone union in fragility fractures of patients with osteoporosis (exploratory research)
Teriparatide multi-facility collaborative controlled trial
Japan |
Fragility fractures due to osteoporosis
Orthopedics |
Others
NO
To evaluate the efficacy and safety of teriparatide by comparing a group treated with a combined preparation of teriparatide, active vitamin D, and calcium against a group treated with a combined preparation of active vitamin D and calcium.
Safety,Efficacy
Exploratory
Explanatory
Not applicable
Radius: Bone union following surgery in patients with distal radius fragility fractures
Femur: Bone union following surgery in patients with proximal femoral fragility fractures
Vertebral body: Bone union in conservative treatment of the vertebral body in patients with fragility fractures
The two treatment groups were compared by assessing the presence or absence of porosis in the fracture area by X-ray and CT at 8 weeks and 12 weeks following surgery to determine bone union and assessing instability in the vertebral body by X-ray.
QOL, bone mass measurement by DXA (lumbar spine, radius (contralateral), proximal femur), bone formation marker (serum P1NP), one resorption marker (TRACP-5b), ucOC, Ca, P, DASH, PRWE-J, grasping power, and periodic change in SF36 were compared between the two treatment groups.
Interventional
Parallel
Non-randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
Alfarol 0.5 microgram+ calcium lactate 2 x 2 g (or calcium aspartate 2 x 800 mg)/day
Teriparatide 56.5 microgram /week
Alfarol 0.5microgram + calcium lactate 2 x 2 g (or calcium aspartate 2 x 800 mg) /day
20 | years-old | <= |
Not applicable |
Male and Female
1) Patients with osteoporosis who have incurred a new bone fracture [bone density (YAM value) of less than 70% for either the lumbar spine, healthy femur or healthy forearm, or previous fragility fracture (fracture due to a mild external force)] and those with radial fracture or proximal femoral fracture subject to open reduction and internal fixation (for the vertebral body, patients subject to conservative treatment).
2) Patients 20 years of age or over at the time of providing consent.
3) Patients who could provide written consent for participation.
1)Patients believed to be at high risk of developing the following osteosarcomas:
(1) Paget's disease of bone
(2) Patients exhibiting elevated alkaline phosphatase levels of unknown origin
(3) Infant and young patients in which the epiphysesal line is not closed
(4) Patients who have received radiation therapy believed to have affected the bones
2) Hypercalcemic patients
3) Patients with a primary malignant osteosarcoma or metastatic osteosarcoma
4) Patients with metabolic bone disease other than osteoporosis (hyperparathyroidism),
Administration was possible if, in patients with a history of secondary hyperparathyroidism, the PTH could be normalized by administration of vitamin D and calcium preparations
5) Pregnant or lactating women, or women who may be pregnant
6) Patients with a history of hypersensitivity to the agents used in this study or to similar compounds
7) Patients with kidney stones
8) Patients with severe renal failure (except when eGFR <30 mL /min/1.73 m2)
9) Patients in a comatose state or those in a state of circulatory collapse
10) Patients strongly under the effect of central nervous system depressants such as barbiturates or narcotics
11) Patients receiving administration of adrenalin
12) Patients who cannot give consent themselves (dementia, etc.)
13) Patients with a history of receiving preparations for PTH
14) Patients who are deemed unsuitable by the attending physician
80
1st name | |
Middle name | |
Last name | Tsuyoshi Murase |
Osaka University Graduate School of Medicine
Orthopaedic Surgery
2-2, Yamada-oka, Suita, Osaka 565-0871
06-6879-3552
tmurase-osk@umin.ac.jp
1st name | |
Middle name | |
Last name | Kosuke Ebina |
Osaka University Graduate School of Medicine
Orthopaedic Surgery
2-2, Yamada-oka, Suita, Osaka 565-0871
06-6879-3552
k-ebina@umin.ac.jp
Osaka University
None
Self funding
None
Minoh City Hospital, Kita-Osaka Police Hospital, Osaka Koseinenkin Hospital, Hoshigaoka Koseinenkin Hospital, Kyoritsu Hospital
None
NO
大阪大学医学部附属病院(大阪府)
2014 | Year | 05 | Month | 14 | Day |
Unpublished
Completed
2013 | Year | 06 | Month | 18 | Day |
2013 | Year | 10 | Month | 01 | Day |
2017 | Year | 06 | Month | 30 | Day |
2014 | Year | 05 | Month | 14 | Day |
2017 | Year | 11 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013476
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |